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Purpose: This study explored the barriers that adult
Americans experience when taking injectable medica-
tions for type 2 diabetes, from the time of ﬁlling the
initial prescription through the decision to discontinue
the medication.
Methods: An Internet-based survey was conducted
in 2 waves among adult patients (N ¼ 2000) who had
received a physician prescription for insulin, liraglu-
tide, or exenatide once weekly (QW), regardless of
whether the prescription was ﬁlled by a pharmacy. In
wave 1, patients were surveyed on their medication
history and experience and, if relevant, the medication
discontinuation process. Those still taking their inject-
able medication at the time of wave 1 were contacted
6 months later (wave 2, n ¼ 585) to assess any
changes in their medication experience.
Findings: Among patients who delayed ﬁlling their
prescription by Z1 week, cost was a common reason
for delay for reﬁlling of liraglutide (63%) and exena-
tide QW (49%). The most commonly reported barrier
to maintaining injectable medication was injection
concerns (42%) such as aversion to needles, pain, or
needle size. Lack of perceived need was the most
common reason for discontinuation for basal (47%)
and prandial/premixed (44%) insulin. For liraglutide,
the most common reason for discontinuation was
experiencing an adverse event (33%); for exenatide
QW, it was injection concerns (38%).
Implications: The diverse barriers we identiﬁed
underscore the need for better patient–prescriber
communication to ensure that newly prescribed in-
jectable medications are consistent with a patient’s
ability or willingness to manage them, to appropri-
ately set expectations about medications, and to
address new barriers that arise during the course ofJuly 2016treatment. (Clin Ther. 2016;38:1653–1664) & 2016
The Authors. Published by Elsevier HS Journals, Inc.
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Patients with type 2 diabetes typically fail to address
hyperglycemia with diet and exercise and require phar-
macotherapy for disease control.1,2 Adherence, deﬁned
by the World Health Organization as “the extent to
which a person’s behavior-taking medication, following
a diet, and/or executing lifestyle changes, corresponds
with agreed recommendations from a healthcare pro-
vider,” is necessary for disease control.3 Nonadherence
to antidiabetic medications results in poor long-term
glycemic control and is consequently linked with
diabetes-associated complications, more health care re-
source utilization, and higher costs.4–9 Aikens and Piette9
found a linear relationship between self-reported non-
adherence and an increase in glycosylated hemoglobin
levels measured 6 months later. Another study found
that patients who were nonadherent to noninsulin
antidiabetic medications, compared with adherent pa-
tients, were signiﬁcantly more likely to be hospitalized or
require an emergency department visit over a 1-year
period.7
Medication nonadherence and nonpersistence, or
discontinuation, have been shown to be particularly1653
Clinical Therapeuticscommon among those taking injectable antidiabetic
medications.10 In a cross-sectional Internet survey of
specialists and primary care physicians from 8 coun-
tries, including the United States, 73% of patients did
not take insulin as prescribed.11 Similarly, another
analysis found those patients initiating treatment with
glucagon-like peptide-1 receptor agonists (GLP-1RAs)
had a 71% higher discontinuation rate in the ﬁrst
6 months compared with those initiating saxagliptin,
with discontinuation deﬁned as a gap of Z60 days
without drug supply available as measured by using
pharmacy claims.12
Nonadherence and nonpersistence to injectable
antidiabetic medications are inﬂuenced by multiple
factors such as tolerability, efﬁcacy, cost of medica-
tions, complexity of a treatment regimen, and patient–
provider interaction.11,13–15 In particular, patients
prescribed insulin have expressed facing additional
difﬁculties in initiating and maintaining treatment that
are not experienced by those taking only oral medi-
cations.11,15 This issue is especially relevant because a
national health interview survey conducted from
2010–2012 found that 29% of Americans with diabetes
use insulin.16 Past survey research analyzing injection
burden with insulin has shown that patients think that
injections are a serious burden, have a negative impact
on quality of life, and would use injections more
regularly if the pain could be relieved.17
However, to our knowledge, no previous studies
have determined which of these difﬁculties are faced
by patients initiating treatment with GLP-1RAs. The
present study was designed to better understand the
barriers to adherence and reasons for discontinuation
that Americans with type 2 diabetes prescribed inject-
able medications face in multiple stages of their treat-
ment, starting from the initial prescription through
maintenance of the medication and ﬁnally to the
decision-making process around discontinuation.PATIENTS AND METHODS
Study Design
This study was a cross-sectional, Internet-based
survey administered in 2 waves. Patients were re-
cruited from all US census regions via the Harris
Interactive Chronic Illness Panel or other third-party
online research panels in the United States. These
panels consist of participants who previously volun-
teered to complete health-based surveys, and they are1654not afﬁliated with any health care or insurance system.
Survey invitations, including information for accessing
the password-protected online survey, were e-mailed
to panel members. Respondents eligible for the survey
were US residents Z18 years of age diagnosed with
type 2 diabetes who reported ever being prescribed at
least 1 of 4 injectable medication types: exenatide
once-weekly (QW), liraglutide, basal insulin, or pran-
dial/premixed insulin. These injectable medications
were selected for study because they have a range of
proﬁles in terms of dosing frequency, cost, adverse
effects, and other attributes expected to be related to
persistence. Exenatide QW is injected subcutaneously
once weekly using a 23-gauge, 5/16″ needle.18
Liraglutide is injected subcutaneously once daily,
and pen needles are prescribed separately.19 It is
initiated at 0.6 mg per day for 1 week, and then
titrated to a higher dose. Both exenatide QW and
liraglutide can be administered any time of day, with
or without meals.18,19 The basal insulins that respond-
ents reported receiving were insulin detemir and
insulin glargine. These are administered once daily at
the same time each day. The dose is individualized,
and needles are prescribed separately. The prandial/
premixed insulins reported by patients were insulin
glulisine, insulin lispro, insulin human, regular human
insulin, and insulin aspart.20–27 These insulins can be
injected with a pen device, using a vial and syringe, or
via an insulin pump. Patient self-monitoring of blood
glucose levels with dose adjustment is recommended.
Respondents who were prescribed a medication but
did not have it ﬁlled by a pharmacy were considered
eligible for relevant sections of the survey. Respond-
ents were accepted until preset quotas for each
medication and discontinuation status were ﬁlled
(N = 2000). In cases in which patients stated that
they had been prescribed 41 of the surveyed medi-
cations, patients were directed to answer questions
about the medication type with the smallest number of
respondents. We refer to the medication about which
the patient answered questions as the “medication of
interest.”
In wave 1 of the study, patients were asked: (1) if
they ﬁlled the medication of interest when ﬁrst
prescribed, time until ﬁlling the prescription, and, if
ﬁlled, how long until they started taking it; (2) about
their reactions to being prescribed an injectable; (3)
for those initiating the medication of interest, if they
discontinued using it; (4) for those discontinuing theVolume 38 Number 7
C.V. Spain et al.medication of interest, the reasons for discontinuing
use and the decision-making process for discontinua-
tion (ie, interactions with physicians and family); (5) if
still taking the medication of interest, what barriers (if
any) to taking it they experienced; and (6) demo-
graphic and clinical characteristics. Respondents also
completed the Diabetes Empowerment Scale (DES), a
measure of psychosocial self-efﬁcacy for people with
diabetes.28 For questions eliciting reasons for a
decision, respondents were allowed to select multiple
reasons from a list and/or to provide a free-text
reason. The order of reasons was randomly deter-
mined for each respondent. Respondents were then
directed to select the main reason. Discontinuation
was self-reported and included both patient-initiated
discontinuation and physician-initiated discontinua-
tion or switching. The investigators compiled the list
of reasons for discontinuation by using previous
studies of diabetic medications and from the clinical
trials of the relevant pharmaceutical products. The
online survey (including a preliminary list of reasons
for discontinuation) was pretested with a small group
of respondents (n ¼ 12) and revised based on
respondent feedback. Institutional review board ap-
proval of the study protocol and survey were obtained
before distribution of the survey invitation.
Wave 2 of the survey was conducted 6 months later
among respondents who were persistent with their
medication of interest at wave 1 and agreed to be
recontacted. These patients (585 respondents of the
1086 persistent patients who agreed to be recontacted)
were asked whether they were still taking their
medication of interest. If not, they were asked about
the discontinuation process.
Data Analysis
For analysis, patients were classiﬁed into 8 sub-
groups: the 4 treatment groups (basal insulin, pran-
dial/premixed insulin, liraglutide, and exenatide QW)
further subdivided into those still taking their inject-
able medication (“continuers”) and those who had
discontinued use (“discontinuers”). Reported reasons
for discontinuation and barriers to taking medication
were categorized into 9 areas: lack of perceived need
(eg, belief disease was already well managed); adverse
events experienced (eg, hypoglycemia, weight gain,
gastrointestinal events); injection concerns (eg, aver-
sion to needles, needle size, pain); cost; health care
provider recommendation (eg, stop or replaceJuly 2016medication); burden/inconvenience (eg, blood glucose
monitoring, injection frequency); lack of perceived
medication beneﬁts (eg, belief medication would not
work); medication concerns (perceived but not expe-
rienced [eg, worry about potential weight gain]); and
not understanding administration (eg, self-injection
difﬁculty). (The Supplemental Table in the online
version at http://dx.doi.org/10.1016/j.clinthera.2016.
05.009 lists reported reasons for discontinuation and
barriers to taking medication.)
Demographic variables were reported as of wave 1.
A weighting algorithm was applied so eligible re-
spondents were appropriately representative of US
residents Z18 years of age with type 2 diabetes based
on education, age, sex, race/ethnicity, region, and
household income. Our weighting algorithm also
adjusted for attitudinal and behavioral differences
between those who are online versus those who are
not, those who join online panels versus those who do
not, and those who responded to this survey versus
those who did not. Each respondent is given a score
based on their reported information and then either
weighted up (if they are underrepresented) or weighted
down (if they are overrepresented). Using z critical
values, 95% CIs for proportions were constructed.RESULTS
At the time of contact for wave 1, a total of 2000
respondents completed the survey: 1155 continuers
and 845 discontinuers, including 47 respondents who
received medication but never ﬁlled their prescription
(eg, only took samples) (ﬁgure). Wave 1 continuers
interested in participating in the follow-up survey (n ¼
1086) were recontacted for wave 2. Of these, 585
were successfully recontacted and completed the wave
2 survey, with 522 (89%) indicating that they were
still taking their medication of interest at that time and
63 (11%) discontinuing use since the time of wave 1
(classiﬁed as “discontinuers” for analytic purposes).
Ten respondents were disqualiﬁed from further anal-
ysis because they provided conﬂicting information
about their diagnosis and/or which medications they
had been prescribed, yielding a total of 1092 contin-
uers and 898 discontinuers across both waves.
Demographic and Baseline Characteristics
The mean age of respondents in each subgroup
ranged from 54 to 58 years, except for exenatide QW1655
2000 respondents:
 • With type 2 diabetes
 • ≥18 years old
 • Taken at least 1 dose of 
qualifying injectable diabetes 
medication
*845 Previously
discontinued the medication
(including 47 who never
filled prescription)
†69 declined to be 
recontacted 
(wave 1 data reported)
†501 did not respond
to wave 2
(wave 1 data reported)
*63 Discontinued 
medication in 6-month period
W
ave 2
6 m
onths
later
W
ave 1
1155 Still taking the
medication
1086 agree to be
 recontacted for wave 2
585 successfully
recontacted
†522 still taking
medication
Figure. Flow diagram of study respondents.
*Discontinued (reported under reasons
for discontinuation in Table IV).
†Continued (reported under medication
barriers in Table IV).
Clinical Therapeuticsdiscontinuers, who had a mean age of 46 years (Table I).
Most respondents had health insurance (Z85%). The
majority of patients reported hypertension or hyper-
cholesterolemia. In the exenatide QW group, more
patients (16%–21%) reported kidney disease than in
the other groups. In addition, a high proportion of those
who discontinued exenatide QW (37%) reported heart
disease. Those who discontinued their medication were
less likely to have health insurance compared with
continuers, except for those prescribed prandial/
premixed insulin. Discontinuers were also more likely
to be injection-naive, with the exception of basal insulin
users. The majority of patients who discontinued taking
either exenatide QW or liraglutide did so during the ﬁrst
6 months of treatment (79% and 50%, respectively).Reaction to Being Prescribed Injectable
Medication
Those patients who reported that the medication of
interest was their ﬁrst injectable diabetes medication
(n ¼ 1201) were asked about their reaction to being
prescribed an injectable. Nervousness about using an
injectable was common for those who initiated1656prandial/premixed insulin (46%–51%) or exenatide
QW (48%–52%) treatment (Table II). Those patients
initiating liraglutide therapy often had a positive
reaction, with 44% of discontinuers and 55% of
continuers reporting feeling encouraged that they
could better manage their diabetes. Depending on
the medication and discontinuation status, 4% to
10% of patients believed that their physicians were
using injectable medications as a threat to encourage
them to take control of managing their diabetes,
except for those prescribed exenatide QW, for
whom it was 24% to 28%.
Timing of Prescription Fill and Medication
Initiation
When asked about the initial prescription, 2% of
respondents reported never ﬁlling it. The proportion
of respondents who delayed ﬁlling this prescription by
at least 1 week was 11% to 18%, depending on the
medication. Injection concerns were frequently cited
as a reason for delay in ﬁlling prandial/premixed
insulin and exenatide QW (30% and 56%, respec-
tively, Table III), with nervousness about using an
injectable commonly reported under this category
(23% and 42%, respectively, data not shown). Cost
was cited as a reason for delay by 63% and 49% of
respondents prescribed liraglutide and exenatide QW.
A high percentage of those prescribed liraglutide
(31%) noted that they were given free samples and
were therefore able to take the medication before
ﬁlling the prescription.
Barriers Experienced by Those Still on Medication
When we asked patients still taking the medication
of interest about their experience, the most commonly
cited barrier to remaining on the medication was
injection concerns (42%) (Table IV); speciﬁc
concerns were preference for oral medications
(23%), needle pain experience (13%), nervousness
about using an injectable (11%), fear of needles
(10%), and needle size (7%). Injection concerns
were more commonly reported among those for
whom the medication was the ﬁrst injectable
prescribed (49% [95% CI, 45–53]) compared with
those with previous injectable experience (28%
reporting injections concerns [95% CI, 24–32]).
Burden/inconvenience was cited by 30% of
continuers, with inconvenience of taking a
medication that needs to be refrigerated mostVolume 38 Number 7
Table I. Study population according to treatment discontinuation status.*
Characteristic
Basal Insulin
Prandial/Premixed
Insulin Liraglutide Exenatide QW
Cont D/C Cont D/C Cont D/C Cont D/C
No. (%) of patients 216 (36) 383 (64) 251 (42) 343 (58) 324 (54) 273 (46) 107 (54) 93 (46)
Mean age, y 54 58 58 56 56 57 46 54
% Male subjects 48 45 57 57 48 47 55 50
Race, %
White 74 77 78 76 86 82 72 64
African American 18 18 18 17 11 10 17 25
American Indian or Alaska
Native
5 1 0 2 0 1 2 5
Asian or Paciﬁc Islander 1 1 1 1 1 2 3 4
Other 1 1 0 1 1 4 3 2†
Ethnicity, %
Hispanic or Latino 10 14 18 13 14 13 14 7
Health insurance, % 85 93 89 86 91 98 94 99
Medicare 40 44 42 42 33 39 32 40
PPO 29 18 22 19 31 28 32 37
HMO 13 14 14 18 16 15 14 5
Other 7 4 9 7 3 5 2 5
Traditional 7 4 5 3 7 7 11 4
Medicaid 3 14 7 9 8 4 9 9
Comorbidity, %
Hypertension 68 64 68 63 65 65 60 56
Hypercholesterolemia 64 66 66 60 63 66 70 73
Heart disease 17 19 14 12 12 18 37 10
Kidney disease 8 9 8 9 12 3 21 16
Mean DES score 3.86 3.81 3.83 3.85 3.78 3.81 3.97 3.91
First injectable, % 67 73 76 66 54 44 69 58
Delayed ﬁlling prescription by
41 wk, %
7 11 5 6 15 14 11 14
Never ﬁlled prescription, % 5 — 2 — 5 — 6 —
On medication for o6 mo
before discontinuation, %
29 — 36 — 50 — 79 —
Cont ¼ continued (ie, taking medication at time of survey); D/C ¼ discontinued; DES ¼ Diabetes Empowerment Scale;
HMO ¼ health maintenance organization; PPO ¼ preferred provider organization; QW ¼ once weekly.
*For wave 2 respondents, discontinuation status is based on wave 2 responses. For those only included in wave 1, the
discontinuation status is based on wave 1 responses.
†Includes no response.
C.V. Spain et al.commonly mentioned (11%). Experiencing adverse
events was a barrier for continuation in 24% of
continuers. The primary adverse events noted byJuly 2016patients currently taking insulin were hypoglycemia
(15%–16%) and weight gain (13%). Gastrointestinal
adverse events were reported as a barrier by 6% to1657
Table II. Initial reaction to being prescribed an injectable medication for managing diabetes (Z20% for any group) among those for whom
medication was first injectable taken. Values are given as percentage (95% CI).
Reaction Choice Selected
Basal Insulin Prandial/Premixed Insulin Liraglutide Exenatide QW
D/C Cont D/C Cont D/C Cont D/C Cont
I was nervous about using an
injectable medication correctly
41 (33–49) 37 (31–43) 51 (44–58) 46 (39–53) 31 (24–38) 33 (25–41) 48 (35–61) 52 (37–67)
I felt encouraged that I could better
manage my diabetes
34 (27–41) 39 (33–45) 28 (22–34) 43 (36–50) 44 (37–51) 55 (46–64) 41 (28–54) 36 (21–51)
I was disappointed that I had not
managed my diabetes better to
avoid using injectable medications
30 (23–37) 35 (29–41) 24 (18–30) 29 (23–35) 22 (16–28) 19 (12–26) 32 (20–44) 39 (24–54)
I was surprised because I thought my
diabetes was being well managed
8 (4–12) 16 (11–21) 4 (1–7) 20 (14–26) 13 (8–18) 14 (8–20) 38 (26–50) 26 (13–39)
I felt that my doctor was using injectable
medication as a threat to encourage
me to take control of managing my
diabetes
8 (4–12) 4 (2–6) 8 (4–12) 10 (6–14) 8 (4–12) 6 (2–10) 28 (17–39) 24 (11–37)
Cont ¼ continued; D/C ¼ discontinued; QW ¼ once weekly.
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Table III. Most commonly reported reasons for delay in filling prescription by Z1 week. Values are given as
percentage (95% CI).
Reason
Basal Insulin
(n ¼ 44)
Prandial/
Premixed
Insulin (n ¼ 34)
Liraglutide
(n ¼ 67)
Exenatide QW
(n ¼ 23)
Cost 21 (9–33) 17 (4–30) 63 (51–75) 49 (29–69)
Lack of perceived need 20 (8–32) 24 (10–38) 12 (4–20) 35 (16–54)
Injection concerns 19 (7–31) 30 (15–45) 22 (12–32) 56 (36–76)
Medication concerns (perceived) 10 (1–19) 13 (2–24) 5 (0–10) 23 (6–40)
Burden/inconvenience 5 (*–11) 19 (6–32) 11 (4–18) 32 (13–51)
Not understanding administration 3 (*–8) 2 (*–7) 4 (*–9) 15 (0–30)
Lack of perceived beneﬁts 0 (0–0) 1 (*–4) 4 (*–9) 9 (*–21)
Other† 34 (20–48) 34 (18–50) 12 (4–20) 19 (3–35)
QW ¼ once weekly.
*Negative lower bound to CI, indicating that the 95% CI includes 0.
†Includes reliance on samples, logistical barriers (eg, requirement to use mail order), and desire to use supplies of previously
prescribed medications.
C.V. Spain et al.8% of patients currently taking GLP-1RAs but by
r2% of those currently taking insulin.
Decision to Discontinue Medication
Overall, 898 respondents had discontinued the
medication of interest: 845 had discontinued before
the initial contact for wave 1, and an additional 53
had discontinued in the 6-month period before wave 2
contact. The decision for patients to discontinue their
injectable medications was primarily made either
jointly with (35%) or solely by (31%) their health
care provider/physician, whereas 23% reported dis-
continuing on their own. Among all patients who
discontinued, 78% reported being prescribed another
medication as a replacement, but among the patients
who discontinued their injectable medication on their
own, only 65% reported ever receiving a replacement
medication. For those patients who were prescribed
insulin, 14% to 19% discontinued on their own
compared with 30% for either GLP-1RA.
Reasons for Medication Discontinuation
The most commonly reported reason for discontin-
uation overall and for insulin was lack of perceived
need (Table IV). The most common reason for
discontinuation of liraglutide was experiencing an
adverse event; for exenatide QW, it was injectionJuly 2016concerns. Similarly, when patients were asked about
the main reason for discontinuation, lack of perceived
need was the most cited main reason for basal and
prandial/premixed insulin and overall (39%, 38%,
and 29%, respectively). Experiencing an adverse event
was the most common main reason for
discontinuation for both liraglutide (32%) and
exenatide QW (23%), and it was also the most
commonly reported reason among those who
discontinued prandial/premixed insulin during the
ﬁrst 3 months of treatment. When we solicited more
details about adverse events, nausea or vomiting was
cited as the main reason for discontinuation by 18%
of patients who discontinued liraglutide and 3% of
patients who discontinued exenatide QW; 8% of
patients who discontinued insulin cited hypoglycemia
as the main reason. Patients who discontinued
liraglutide commonly cited cost and lack of
perceived need as the main reason (23% and 16%),
whereas those who discontinued exenatide QW cited
injection concerns and burden/inconvenience as the
main reason (22% and 14%).
Further calculations were conducted to evaluate the
hypothesis that discontinuation in the ﬁrst 6 months
of treatment may represent the physician’s decision to
switch a patient from a GLP-1RA to insulin because of
insufﬁcient glycemic control. Among those who1659
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1660discontinued their medication in the ﬁrst 6 months,
the proportion who discontinued because of lack of
perceived beneﬁt was 9% for basal insulin (95% CI,
2–16), 1% for prandial insulin (95% CI, 0–3), 18%
for liraglutide (95% CI, 12–24), and 23% for exena-
tide QW (95% CI, 14–32).DISCUSSION
This study identiﬁed a diverse range of concerns that
patients with type 2 diabetes faced when initiating or
maintaining an injectable medication. Although some
concerns were reported frequently across all medica-
tions, others were commonly seen for certain
medication types.
Among these 4 types of medication, injection
concerns were commonly faced, even among those
still taking their injectable medication. Speciﬁcally,
patients commonly reported nervousness about using
an injectable, preference for oral medications, fear of
needles, and needle size/pain as either a reason for
delayed prescription fulﬁllment, a barrier to maintain-
ing therapy, or a reason for discontinuation. These
concerns are consistent with previous data showing
that 33% of patients are anxious about taking their
insulin injections.29,30 For those who were prescribed
exenatide QW, the relatively high frequency of in-
jection concerns may be related to patient concern
over the 8-mm, 23-gauge needle, the required mixing
procedures, or the perception that physicians were
using the prescription as a threat.18,31
Among patients prescribed insulin, the commonly
reported lack of perceived need may be reﬂective of
the large proportion of patients with diabetes who are
asymptomatic and/or do not have their glycemic
control monitored. These results are comparable with
those found in a survey of patients with chronic
diseases, including diabetes, in which lack of perceived
need was mentioned as a common reason for medi-
cation nonfulﬁllment and nonpersistence in 25% and
23% of respondents, respectively.32 The low
proportion of continuers reporting lack of need
(9%) may reﬂect that awareness of the need for
glycemic control is a motivator to persist on
treatment.15 Burden/inconvenience was the second
most cited barrier in this study for patients to
maintain their insulin therapy, consistent with
previous ﬁndings on the challenges of managing
insulin.29,30Volume 38 Number 7
C.V. Spain et al.Not surprisingly, hypoglycemia and weight gain
were speciﬁcally cited by patents on insulin therapy as
both a barrier to maintaining treatment and a reason
for discontinuation. These ﬁndings are consistent with
previous research showing that experience and fear of
hypoglycemia associated with insulin use can lead to
decreased medication adherence, poorer adherence,
and more perceived barriers to taking the medica-
tion.33–35
Weight gain is particularly problematic for patients
with type 2 diabetes because many are already over-
weight at diagnosis.36,37 In the DAWN (Diabetes Atti-
tudes, Wishes and Needs) study, for example, 25.1%
of patients with diabetes expressed substantial con-
cern about their weight, which was associated with
lower self-rated health, reduced adherence, poorer
psychological well-being, and increased diabetes-
related distress.37
For GLP-1RAs, after injection concerns, adverse
events and perceived medication concerns were the
most frequent barriers and reasons for discontinua-
tion. Gastrointestinal adverse events, in particular,
were cited as a barrier to continued use of GLP-
1RAs. This ﬁnding is consistent with Phase III trial
results in which nausea, vomiting, and diarrhea were
common adverse events with the GLP-1RAs.18,19
Burden/inconvenience was also frequently mentioned
as a medication barrier and reason for discontinuation
for patients using exenatide QW, potentially due to
the mixing procedure that was required.18,31
The majority of patients discontinuing GLP-1RAs
did so before 6 months of therapy. Some of the
reasons for discontinuation cited by respondents
previously taking GLP-1RAs are those likely to be
experienced early in the course of therapy, such as
injection concerns, adverse events, and cost. The
economic burden of injectable drugs, particularly
GLP-1RAs, may inﬂuence decisions on medication
choice and persistence.38,39 In a study of patients with
type 2 diabetes from an economically burdened region
in which up to 50% underused their medication, cost
was cited as a primary reason for underuse.38
Consistent with these ﬁndings, cost was cited in our
study as a reason for delay in ﬁlling prescriptions, as a
barrier to medication continuation, and as a reason
for discontinuation. Those who discontinued a GLP-
1RA in the ﬁrst 6 months of therapy commonly
reported lack of medication beneﬁt as a reason. This
pattern is consistent with the clinical scenario in whichJuly 2016a patient is found to have insufﬁcient glycemic control
during the ﬁrst 6 months of a new therapy and the
physician therefore switches the patient to insulin.
Several of our ﬁndings suggest that patients either
did not receive sufﬁcient education on their injectable
medication and/or did not retain key information
from the training. For example, although patients
taking insulin do not typically need to keep the
product refrigerated, refrigeration was reported as a
barrier to taking the medication. Unlike previous
studies that found an association of low self-efﬁcacy
with resistance to using insulin and reduced adher-
ence,40,41 we found no difference in self-efﬁcacy,
based on DES score, between continuers and discon-
tinuers. Research on psychological barriers to initiat-
ing insulin highlights concerns about self-efﬁcacy to
manage injections and the concept that some patients
may feel that starting insulin reﬂects a personal failure
to control their diabetes with other methods.40 The
similarly high DES scores for both continuers and
discontinuers may be a consequence of the self-
selected nature of the sample, but regardless, it shows
that patients with high self-efﬁcacy still ﬁnd aspects of
injectable antidiabetic medications to be barriers to
maintaining therapy.
Because prescribers have reportedly used insulin as
a threat to try to get patients to adhere to treatment
recommendation,15 we were interested in evaluating
patient threat perception in the present study.
Approximately 25% of patients prescribed exenatide
QW perceived injectable medication being used as a
threat to motivate behavior change, whereas this
perception appeared to be less common for those
prescribed insulin or liraglutide. In fact, the most
common reaction among patients being prescribed
liraglutide was feeling encouraged that they could
better manage their diabetes. A report on barriers to
insulin use by Polonsky and Jackson42 suggests that
one of the keys to helping patients overcome their
individual barriers to initiation is for the prescriber to
frame the medication positively.
It is notable that 23% of patients discontinued
medication without consulting their provider. Further-
more, 22% of patients who discontinued were not
given a replacement medication, which may reﬂect a
lack of knowledge on the part of the prescriber that
the patient was no longer taking the injectable
medication. If this decision was taken without dis-
cussion with their physician, the chance to prescribe a1661
Clinical Therapeuticsreplacement medication may have been missed.
Understanding more about the decision-making proc-
ess may encourage prescribers to better communicate
with their patients to avoid gaps in treatment that
could potentially lead to worsened glucose control
and long-term complications.
Certain limitations apply to a study of this nature.
Because patients who responded to the survey were
not a random sample and were required to have a
computer with Internet access, the representative
nature of the study may have been affected. The high
rates of insurance coverage mean that these results
may not be generalizable to an uninsured population.
A weighting algorithm accounting for demographic
and attitudinal characteristics was applied to minimize
the potential impact of selection biases.
An additional limitation of the survey was its
retrospective nature and consequent dependence on
the memory of respondents and potential for recall
errors. Self-reporting of which medications were
prescribed may not be accurate, although we took
several steps to reduce errors, including providing
visual images of the medication container. In addition,
those using medication only for a short time may be
less likely to remember and report having received it.
In that case, these results may underrepresent the
experiences of those who discontinued treatment
quickly.CONCLUSIONS
Our ﬁndings indicate the need to establish programs
whereby information is routinely solicited from pa-
tients so that medication selection is consistent with
patient preferences and ability/willingness to manage
a particular medication. Once on medication, there is
a need for ongoing monitoring and support to
identify and address new barriers that arise. An
example of such an initiative is the Medication
Monitoring and Optimization Program utilized by
community pharmacies in the Netherlands, which
employed continuous patient-centered pharmaceutical
care for those with chronic diseases to signiﬁcantly
reduce treatment discontinuation in patients with
osteoporosis and hyperlipidemia.43 Understanding a
patient’s thought process may aid physicians in
motivating their patients to overcome barriers to
ﬁlling and using prescribed injectable medication for
type 2 diabetes.1662ACKNOWLEDGMENTS
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Table S1Table S1. Reported reasons for discontinuation and barriers to taking medication by category for analysis.
Category for analysis Reason
Injection concerns  I was nervous about using an injectable diabetes medication
 I prefer medications I can take by mouth (such as pills or tablets) instead
of shots
 I am afraid of needles
 I was concerned about the needle size
 I experienced needle pain from injecting
Burden/inconvenience
 Testing my blood sugar was too inconvenient
 Testing my blood sugar was too painful
 It was more of a hassle than it was worth
 It was too difﬁcult to plan my daily activities around the medication
 It was too inconvenient to take a shot every day
 It was too inconvenient to take a medication that needs to be refrigerated
 It was too inconvenient to take a medication that had to be injected
Adverse events
(experienced)
 I experienced skin lumps from the injections
 I experienced itchiness, rash, or other reactions where the shot was injected
 It made me gain weight
 It made me feel more tired
 It caused me to experience diarrhea, gas, or bloating
 I experienced hypoglycemia (low blood sugar)
 It made me sick to my stomach or made me throw up (nausea or vomiting)
Medication concerns
(perceived)
 I was worried that I would gain weight
 I was worried it would interfere with other medications that I take
 I was worried that it would make me sick to my stomach or make me throw up
(nausea or vomiting)
 I read or heard news reports about problems with the medication
 I was concerned that it was going to hurt my health
Lack of perceived need
 I did not think I needed to be on an injectable medication
 I felt that my diabetes was being well managed without medication
 I was able to manage my diabetes with changes to my diet and exercise
 I lost weight another way (for example, diet or surgery)
Cost
 The medication was too expensive
 My health insurance never paid for it
 My health insurance stopped paying for it
Lack of perceived beneﬁts
 The medication did not control my blood sugar well enough
 I did not believe the medication would work
Not understanding
administration
 I was not sure how to use the medication
 I didn’t understand the instructions for taking my medication
 I wasn’t sure how to give myself the injection
Health care provider
recommendation
 My doctor replaced it with a different medication
 My doctor took me off the medication without starting another one
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